At a glance
- Serelaxin is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 235 publications mentioning it, including 36 randomized controlled trials and 31 animal-only studies.
- ClinicalTrials.gov lists 17 registered studies testing it (0 active).
- FDA's adverse event system (FAERS) holds 53 reports mentioning it; 52 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Relaxin-2: Shaping the Proteomic Landscape of Skeletal Muscle Physiology, Glucose Trafficking, and Mitochondrial Function in Rat.
- Correction to "Combining mesenchymal stem cells with serelaxin provides enhanced renoprotection against 1 K/DOCA/salt-induced hypertension".
- EXPRESSION OF CONCERN: Serelaxin-Mediated Signal Transduction in Human Vascular Cells: Bell-Shaped Concentration-Response Curves Reflect Differential Coupling to G Proteins.
- Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease.
- Serelaxin alleviates ischemia reperfusion-induced kidney injury by modulating inflammatory response and inhibiting of notch-2/hes-1 signaling pathway.
- Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure.
- Clinical Presentation, Biomarker Trajectories, and Outcomes in Women and Men Hospitalized for Acute Heart Failure.
- Long-acting relaxin analogues: a novel tool in cardiology.
- Relaxin-2 Ameliorates Spinal Cord Injury by Inhibiting Microglia Activation.
- End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2).
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 17
- Active
- 0
- With posted results
- 10
Conditions studied
Show 7 more studies
| Study | Status | Phase | Start |
|---|---|---|---|
| Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia | Terminated | Phase 2 | May 2013 |
| An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension | Completed | Phase 2 | Apr 2013 |
| Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure | Completed | Phase 2 | Mar 2012 |
| Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF) | Completed | Phase 2 | Feb 2012 |
| Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects | Completed | Phase 1 | Jul 2011 |
| Recombinant Human Relaxin for the Treatment of Decompensated CHF | Terminated | Phase 2 | Nov 2006 |
| Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor | Completed | Phase 2 | Nov 2005 |
All 17 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 53
- Serious
- 52
- With death outcome
- 7
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.